Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
about
BRCA1 and BRCA2 mutations and treatment strategies for breast cancer.Contralateral risk-reducing mastectomy: review of risk factors and risk-reducing strategies.Trends of triple negative breast cancer research (2007-2015): A bibliometric study.Can we prevent BRCA1-associated breast cancer by RANKL inhibition?Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review.Patterns of Occurrence and Outcomes of Contralateral Breast Cancer: Analysis of SEER Data.
P2860
Q33894431-A0D210D9-F8C0-4A0C-B373-0B93466BF432Q35066801-78C6650A-EB09-4841-9056-CFEB3E55F4C7Q37433105-0926B4DD-3C0F-4794-A747-1B49D56B0C27Q38991293-18633A5E-4024-41EF-88F7-776993716705Q40592257-70535D34-6D84-4D1F-853C-E0D79AF16EC0Q41696217-A96C10F6-6F86-4035-9C1C-FD92F6A5C7F9Q55515741-E31FCAA3-6BBD-4690-B289-D1A0F224F2A6
P2860
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Duration of tamoxifen use and ...... A1 and BRCA2 mutation carriers
@ast
Duration of tamoxifen use and ...... A1 and BRCA2 mutation carriers
@en
Duration of tamoxifen use and ...... A1 and BRCA2 mutation carriers
@nl
type
label
Duration of tamoxifen use and ...... A1 and BRCA2 mutation carriers
@ast
Duration of tamoxifen use and ...... A1 and BRCA2 mutation carriers
@en
Duration of tamoxifen use and ...... A1 and BRCA2 mutation carriers
@nl
prefLabel
Duration of tamoxifen use and ...... A1 and BRCA2 mutation carriers
@ast
Duration of tamoxifen use and ...... A1 and BRCA2 mutation carriers
@en
Duration of tamoxifen use and ...... A1 and BRCA2 mutation carriers
@nl
P2093
P2860
P50
P1476
Duration of tamoxifen use and ...... A1 and BRCA2 mutation carriers
@en
P2093
Andre Robidoux
Andrea Eisen
Charis Eng
Charmaine Kim-Sing
Christian F Singer
Dawna M Gilchrist
Henry T Lynch
Hereditary Breast Cancer Clinical Study Group
Howard Saal
Jacek Gronwald
P2860
P2888
P304
P356
10.1007/S10549-014-3026-3
P407
P50
P577
2014-06-21T00:00:00Z
P6179
1034212975